IL6 and breast cancer: TEVs can modify or block the differentiation of immature myeloid cells (IMC) to DC or divert the DCs maturation from IMC to MDSC or M2 macrophage (Table 2 and Table 3) by interacting with bone marrow IMC and inducing the production of IL-6, and decreasing expression of CD83 and CD86, as reported for breast cancer, murine mammary adenocarcinoma, and melanoma [149,150].